The dopamine transporter (DAT) is a target of amphetamine (AMPH) and cocaine. These psychostimulants attenuate DAT clearance efficiency, thereby increasing synaptic dopamine (DA) levels. Re-uptake rate is determined by the number of functional transporters at the cell surface as well as by their turnover rate. Here, we present evidence that DAT substrates, including AMPH and DA, cause internalization of human DAT, thereby reducing transport capacity. Acute treatment with AMPH reduced the maximal rate of Dopamine (DA) signaling in the central nervous system mediates a wide variety of physiologic functions such as movement, motivational control of voluntary behavior, and lactation (1, 2). The magnitude and duration of DA signaling is defined by the amount of vesicular release, the sensitivity of the DA receptors, and the efficiency of DA clearance. The DA transporter (DAT) is largely responsible for regulating DA clearance (3).Psychostimulants, such as cocaine and amphetamine (AMPH), induce DA overflow into the synaptic cleft by acting on the DAT, thereby enhancing dopaminergic transmission (4). Cocaine acts by inhibiting the re-uptake of released DA (5, 6). AMPH-like drugs, however, are thought to promote the release of the transmitter (carrier-mediated efflux) as well as to inhibit its uptake (7,8). Repeated administration of AMPH has been shown to sensitize monoaminergic synapses to subsequent psychostimulant challenge (9). Furthermore, administration of a single, high dose of AMPH acutely (1 h) decreased DAT function in vivo as assessed in striatal synaptosomes prepared from drug-treated rats (10). In contrast, administration of a high dose of cocaine had no effect on subsequent transporter activity (10).To explore the mechanism for the differential effects of AMPH and cocaine on the homeostatic uptake capacity of the human DAT (hDAT), we stably expressed a FLAG-tagged hDAT in EM4 cells (see Materials and Methods). The use of the FLAG fusion protein has provided the opportunity for confocal microscopy analysis of trafficking of the transporter in cells. Here, we report that AMPH caused the hDAT to redistribute intracellularly in a dynamindependent manner, consequently reducing subsequent DA transport capacity. These results provide a mechanism for the AMPHinduced elevation of synaptic DA mediated through a reduction of the number of transporters on the cell surface. Materials and MethodsCell Culture. We created a synthetic hDAT gene, which was tagged at the amino terminus with a FLAG epitope. The gene encodes a protein with an amino acid sequence identical to that of wild-type hDAT with the Met at position 1 replaced by MDYKDDDDKA, but the nucleotide sequence was altered to increase the number of unique restriction sites and to optimize codon utilization. The nucleotide sequence of this construct and its creation will be described elsewhere. The FLAG-tagged syntheticDAT was subcloned into a bicistronic expression vector that expresses the syntheticDAT from a cytomegalovirus promoter and the hygromycin resista...

The magnitude and duration of dopamine (DA) signaling is defined by the amount of vesicular release, DA receptor sensitivity, and the efficiency of DA clearance, which is largely determined by the DA transporter (DAT). DAT uptake capacity is determined by the number of functional transporters on the cell surface as well as by their turnover rate. Here we show that inhibition of phosphatidylinositol (PI) 3-kinase with LY294002 induces internalization of the human DAT (hDAT), thereby reducing transport capacity. Acute treatment with LY294002 reduced the maximal rate of and hDAT cell surface expression was inhibited by expression of a dominant negative mutant of dynamin I, indicating that dynamin-dependent trafficking can modulate transport capacity. These data implicate DAT trafficking in the hormonal regulation of dopaminergic signaling, and suggest that a state of chronic hypoinsulinemia, such as in diabetes, may alter synaptic DA signaling by reducing the available cell surface DATs.

The dopamine transporter (DAT) regulates the clearance of dopamine (DA) released into the extracellular space and is an important site on which psychostimulants act to produce their effects. Here, we show that mitogen-activated protein kinase (MAPK) regulates the transport capacity and intracellular trafficking of DAT. Incubation of striatal synaptosomes or epitope-tagged human DAT (hDAT) human embryonic kidney (HEK) 293 cells with the MAPK kinase (MEK) inhibitors 1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto) butadiene and 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one decreased DA uptake in a concentration- and time-dependent manner. Kinetic studies revealed a decrease in the capacity of transport (Vmax) but no change in Km. Immunoblotting confirmed labeling of p42 and p44 MAPK in untreated striatal synaptosomes and HEK 293 cells, consistent with constitutive MAPK activation, and the inhibitors used decreased MAPK phosphorylation. Biotinylation and confocal imaging studies showed that MAPK inhibition promoted the clathrin-associated redistribution of hDAT from the plasma membrane to the cytosol. In contrast, transient transfection of hDAT-expressing cells with constitutively active MEK increased the Vmax of DA transport without altering Km. However, only a small increase in hDAT cell surface expression was seen. These data demonstrate an involvement of the MAPK cascade in regulating DAT transport capacity in striatum and that inhibition of this cascade decreases DAT cell surface expression in HEK 293 cells. Furthermore, they highlight the potential role of MAPK as a presynaptic mechanism that regulates DA signaling.